GLP-1 Opportunity Senn Chemicals AG is actively developing GLP-1 based APIs in collaboration with Granules India, presenting a near-term opportunity to offer enabling scale-up, cGMP manufacturing, and regulatory support services for peptide-based therapeutics.

Acquisition Signal Recent acquisition by Granules India for CHF 20 million signals strategic consolidation and potential access to Senn's CDMO capabilities, suggesting opportunities for joint ventures, licensing, or extended manufacturing partnerships.

Peptide Capability Longstanding peptide expertise since 1963 with end-to-end services from discovery to commercial production positions Senn as a reliable partner for peptide API development, scale-up, and cGMP production needing new clients or expansion projects.

Global Reach Headquartered near Zurich and serving biotech, pharma, diagnostics, cosmeceutical, and veterinary clients worldwide, Senn offers international exposure and could be a target for global supply agreements, regional expansion, or supplier diversification.

Growth Potential Current revenue range and a focused portfolio of peptides, amino acid derivatives, nucleotides, and excipients indicate upside through additional peptide APIs, process development, analytical services, and regulatory support for new product introductions.